Last 7 days
-14.4%
Last 30 days
-39.7%
Last 90 days
-47.9%
Trailing 12 Months
-92.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 7.3% | 1,981,872,000 | 1,846,673,000 | 1,290,940,000 | 1,403,032,000 | 1,146,290,000 |
S&GA Expenses | 18.8% | 488,691,000 | 411,242,000 | 366,159,000 | 331,160,000 | 298,358,000 |
R&D Expenses | -36.3% | 1,235,278,000 | 1,940,385,000 | 2,044,283,000 | 2,325,320,000 | 2,534,508,000 |
Costs and Expenses | -14.5% | 2,626,608,000 | 3,072,501,000 | 2,696,723,000 | 2,671,684,000 | 2,832,866,000 |
EBITDA | 51.7% | -604,713,000 | -1,252,892,000 | -1,406,213,000 | -1,249,250,000 | - |
EBITDA Margin | 55.0% | -0.31 | -0.68 | -1.09 | -0.89 | - |
Earnings Before Taxes | 49.7% | -653,647,000 | -1,298,813,000 | -1,449,062,000 | -1,288,764,000 | -1,714,536,000 |
EBT Margin | 53.1% | -0.33 | -0.70 | -1.12 | -0.92 | - |
Interest Expenses | -2.6% | 19,880,000 | 20,417,000 | 21,430,000 | 21,164,000 | 21,127,000 |
Net Income | 50.2% | -657,939,000 | -1,321,974,000 | -1,475,792,000 | -1,317,624,000 | -1,743,751,000 |
Net Income Margin | 53.6% | -0.33 | -0.72 | -1.14 | -0.94 | - |
Free Cahsflow | 30.8% | -503,944,000 | -728,573,000 | -428,649,000 | 322,946,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -0.4% | 2,259 | 2,267 | 2,623 | 2,835 | 2,577 |
Current Assets | -3.2% | 1,703 | 1,760 | 2,136 | 2,347 | 2,155 |
Cash Equivalents | 4.4% | 1,337 | 1,281 | 1,376 | 1,571 | 1,515 |
Inventory | -55.5% | 37.00 | 82.00 | 256 | 107 | 9.00 |
Net PPE | 15.2% | 294 | 256 | 255 | 247 | 226 |
Goodwill | 7.5% | 126 | 118 | 123 | 131 | 131 |
Liabilities | 2.1% | 2,893 | 2,833 | 3,040 | 2,770 | 2,928 |
Current Liabilities | 47.5% | 2,460 | 1,668 | 2,156 | 2,261 | 2,390 |
Shareholder's Equity | -1070.7% | -634 | 65.00 | -351 | - | - |
Retained Earnings | -4.5% | -4,275 | -4,093 | -3,925 | -3,414 | -3,617 |
Additional Paid-In Capital | 2.7% | 3,738 | 3,641 | 3,605 | 3,566 | 3,352 |
Accumulated Depreciation | - | 30.00 | - | - | - | - |
Shares Outstanding | 9.6% | 86.00 | 78.00 | 78.00 | 78.00 | 76.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 35.1% | -415 | -640 | -743 | -428 | 323 |
Share Based Compensation | -3.3% | 130 | 135 | 148 | 163 | 184 |
Cashflow From Investing | -6.5% | -92.98 | -87.28 | -69.96 | -58.28 | 100 |
Cashflow From Financing | 346.2% | 325 | 73.00 | 88.00 | 45.00 | 462 |
100%
100%
95.8%
Y-axis is the maximum loss one would have experienced if Novavax was unfortunately bought at previous high price.
-17.8%
-33.0%
-32.8%
-11.1%
FIve years rolling returns for Novavax.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | -664 | 1,336 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -11,000 | 13,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | unchanged | - | 154 | 154 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -1.38 | -557,575 | 701,425 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -7,856,000 | - | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | - | -16,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 21.56 | -2,465 | 7,535 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | reduced | -41.18 | -20,327 | 2,673 | -% |
2023-02-16 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | new | - | 1,623 | 1,623 | -% |
2023-02-15 | Bridgefront Capital, LLC | new | - | 108,690 | 108,690 | 0.08% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 10.41% | 8,844,653 | SC 13G/A | |
Feb 02, 2023 | state street corp | 7.15% | 6,076,518 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 5.7% | 4,808,261 | SC 13G/A | |
Mar 11, 2022 | blackrock inc. | 5.8% | 4,410,761 | SC 13G/A | |
Feb 14, 2022 | ra capital management, l.p. | 2.8% | 2,097,794 | SC 13G/A | |
Feb 08, 2022 | blackrock inc. | 5.8% | 4,410,761 | SC 13G | |
Feb 16, 2021 | d. e. shaw & co, l.p. | 0.2% | 110,645 | SC 13G/A | |
Feb 16, 2021 | ra capital management, l.p. | 6.0% | 3,788,564 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 8.79% | 5,598,760 | SC 13G | |
Feb 05, 2021 | blackrock inc. | 8.1% | 5,137,631 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | 2.20 -63.15% | 21.52 260.47% | 53.46 795.48% | 116.83 1856.95% |
Current Inflation | - - | 1.33 -77.72% | 18.33 207.04% | 45.97 670.02% | 100.50 1583.42% |
Very High Inflation | - - | 0.27 -95.48% | 14.51 143.05% | 37.13 521.94% | 81.41 1263.65% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 8-K | Current Report | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 3 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-10 | Kelly James Patrick | sold (taxes) | -16,110 | 6.52 | -2,471 | evp, cfo and treasurer |
2023-03-10 | Kelly James Patrick | acquired | 30,050 | 6.52 | 4,609 | evp, cfo and treasurer |
2023-03-10 | Trizzino John | sold (taxes) | -16,110 | 6.52 | -2,471 | evp, cco and cbo |
2023-03-10 | Herrmann John A III | acquired | 30,050 | 6.52 | 4,609 | evp, chief legal officer |
2023-03-10 | Glenn Gregory M | sold (taxes) | -15,856 | 6.52 | -2,432 | president, r&d |
2023-03-10 | Glenn Gregory M | bought | 6,500 | 6.5 | 1,000 | president, r&d |
2023-03-10 | Trizzino John | acquired | 30,050 | 6.52 | 4,609 | evp, cco and cbo |
2023-03-10 | Glenn Gregory M | acquired | 41,063 | 6.52 | 6,298 | president, r&d |
2023-03-10 | Herrmann John A III | sold (taxes) | -11,605 | 6.52 | -1,780 | evp, chief legal officer |
2023-03-07 | Glenn Gregory M | bought | 14,088 | 7.044 | 2,000 | president, r&d |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Revenues | $ 1,981,872,000 | $ 1,146,290,000 | $ 475,598,000 |
Expenses: | |||
Cost of sales | 902,639,000 | 0 | 0 |
Research and development | 1,235,278,000 | 2,534,508,000 | 747,027,000 |
Selling, general, and administrative | 488,691,000 | 298,358,000 | 145,290,000 |
Total expenses | 2,626,608,000 | 2,832,866,000 | 892,317,000 |
Loss from operations | (644,736,000) | (1,686,576,000) | (416,719,000) |
Other income (expense): | |||
Interest expense | (19,880,000) | (21,127,000) | (15,145,000) |
Other income (expense) | 10,969,000 | (6,833,000) | 13,605,000 |
Loss before income tax expense | (653,647,000) | (1,714,536,000) | (418,259,000) |
Income tax expense | 4,292,000 | 29,215,000 | 0 |
Net loss | $ (657,939,000) | $ (1,743,751,000) | $ (418,259,000) |
Net loss per share: | |||
Basic (in usd per share) | $ (8.42) | $ (23.44) | $ (7.27) |
Diluted (in usd per share) | $ (8.42) | $ (23.44) | $ (7.27) |
Weighted average number of common shares outstanding: | |||
Basic (in shares) | 78,183 | 74,400 | 57,554 |
Diluted (in shares) | 78,183 | 74,400 | 57,554 |
Product sales | |||
Revenue: | |||
Revenues | $ 1,554,961,000 | $ 0 | $ 0 |
Grants | |||
Revenue: | |||
Revenues | 382,921,000 | 948,709,000 | 453,210,000 |
Royalties and other | |||
Revenue: | |||
Revenues | $ 43,990,000 | $ 197,581,000 | $ 22,388,000 |
CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,336,883,000 | $ 1,515,116,000 |
Restricted cash | 10,303,000 | 11,490,000 |
Accounts receivable | 82,375,000 | 454,993,000 |
Inventory | 36,683,000 | 8,872,000 |
Prepaid expenses and other current assets | 237,147,000 | 164,648,000 |
Total current assets | 1,703,391,000 | 2,155,119,000 |
Property and equipment, net | 294,247,000 | 225,741,000 |
Total non-current ROU assets | 106,241,000 | 40,123,000 |
Goodwill | 126,331,000 | 131,479,000 |
Other non-current assets | 28,469,000 | 24,291,000 |
Total assets | 2,258,679,000 | 2,576,753,000 |
Current liabilities: | ||
Accounts payable | 216,517,000 | 127,050,000 |
Accrued expenses | 591,158,000 | 673,731,000 |
Deferred revenue | 370,137,000 | 1,422,944,000 |
Current portion of finance lease liabilities | 27,196,000 | 130,533,000 |
Convertible notes payable | 324,881,000 | 0 |
Other current liabilities | 930,055,000 | 36,061,000 |
Total current liabilities | 2,459,944,000 | 2,390,319,000 |
Deferred revenue | 179,414,000 | 172,528,000 |
Convertible notes payable | 166,466,000 | 323,458,000 |
Non-current portion of finance lease liabilities | 31,238,000 | 0 |
Other non-current liabilities | 55,695,000 | 42,121,000 |
Total liabilities | 2,892,757,000 | 2,928,426,000 |
Commitments and contingencies (Note 18) | ||
Preferred stock, $0.01 par value, 2,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021 | 0 | 0 |
Stockholders’ equity (deficit): | ||
Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2022 and 2021; and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December 31, 2021 | 868,000 | 764,000 |
Additional paid-in capital | 3,737,979,000 | 3,351,967,000 |
Accumulated deficit | (4,275,889,000) | (3,617,950,000) |
Treasury stock, 766,631 shares, cost basis at December 31, 2022 and 591,980 shares, cost basis at December 31, 2021 | (90,659,000) | (85,101,000) |
Accumulated other comprehensive loss | (6,377,000) | (1,353,000) |
Total stockholders’ equity (deficit) | (634,078,000) | (351,673,000) |
Total liabilities and stockholders’ equity (deficit) | $ 2,258,679,000 | $ 2,576,753,000 |